Citius Pharmaceuticals (CTXR) Metrics: History & Chart

Citius Pharmaceuticals, Inc.(CTXR)

Biotechnology · Cranford, NJ

$0.50-0.02 (-3.52%)

Delayed quote: Oct 6, 2026, 12:19 PM EDT

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Cranford, NJ

23 employees

www.citiuspharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Leonard L. Mazur

View full financials

Third-Party DCF Estimate (FMP)	$0.92
Price Gap vs Third-Party Estimate	+76.99%

7D Total Return	-5.28%
30D Total Return	-11.52%
YTD Total Return	-33.08%
1Y Total Return	-62.04%
3Y Total Return	-96.89%
5Y Total Return	-98.98%
10Y Total Return	-99.80%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-33.08%
2025	-80.57%
2024	-78.85%
2023	-4.25%
2022	-48.70%
2021	+50.98%
2020

CAGR TTM	-61.87%
CAGR 3Y	-68.55%
CAGR 5Y	-60.04%
CAGR 10Y	-46.34%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

CTXR Valuation Metrics

CTXR Stock Price Metrics

CTXR Dividend Metrics

CTXR Growth Rate Metrics

CTXR Discounted Cash Flow Metrics

CTXR Returns By Period

CTXR Yearly Returns

CTXR Average Annual Returns By Period (CAGR)

CTXR Revenue Metrics

CTXR PE Ratio Metrics

CTXR PS Ratio Metrics

CTXR PB Ratio Metrics

CTXR Price to Free Cash Flow Ratio Metrics

CTXR Debt to Equity Ratio Metrics

CTXR PEG Ratio Metrics

CTXR FCF Yield

CTXR Earnings Yield

CTXR EBITDA Yield

CTXR OCF Yield

CTXR EV/EBIT Ratio Metrics

CTXR EV/EBITDA Ratio Metrics

CTXR EV/Assets Ratio Metrics

CTXR EV/Sales Ratio Metrics

CTXR Current Ratio Metrics

CTXR Quick Ratio Metrics

CTXR ROIC Metrics

CTXR Return on Assets Metrics

CTXR Return on Equity Metrics

CTXR Net Profit Margin Metrics

CTXR Gross Profit Margin Metrics

CTXR Tax Rate Metrics

PS Ratio	1.92
PS Ratio Avg TTM	3.04
PS Ratio Avg 3Y	3.04
Current VS TTM Avg	-36.82%
Current VS 3Y Avg	-36.82%
Current VS 5Y Avg	-36.82%

PB Ratio	0.20
PB Ratio Avg TTM	0.21
PB Ratio Avg 3Y	0.76
Current VS TTM Avg	-6.88%
Current VS 3Y Avg	-73.85%
Current VS 5Y Avg	-98.28%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.11
Debt/Equity Ratio Avg TTM	0.04
Debt/Equity Ratio Avg 3Y	0.01
Current VS TTM Avg	+170.00%
Current VS 3Y Avg	+834.95%
Current VS 5Y Avg	+1328.88%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	117.63
Ev/Ebitda Ratio Avg TTM	116.01
Ev/Ebitda Ratio Avg 3Y	116.01
Current VS TTM Avg	+1.39%
Current VS 3Y Avg	+1.39%
Current VS 5Y Avg	+1.39%

Ev/Assets Ratio	0.03
Ev/Assets Ratio Avg TTM	0.07
Ev/Assets Ratio Avg 3Y	0.53
Current VS TTM Avg	-58.92%
Current VS 3Y Avg	-94.37%
Current VS 5Y Avg	-99.71%

Ev/Sales Ratio	0.53
Ev/Sales Ratio Avg TTM	1.89
Ev/Sales Ratio Avg 3Y	1.89
Current VS TTM Avg	-71.92%
Current VS 3Y Avg	-71.92%
Current VS 5Y Avg	-71.92%

Current Ratio	0.84
Current Ratio Avg TTM	0.70
Current Ratio Avg 3Y	2.67
Current VS TTM Avg	+19.69%
Current VS 3Y Avg	-68.57%
Current VS 5Y Avg	-85.14%

Quick Ratio	0.40
Quick Ratio Avg TTM	0.25
Quick Ratio Avg 3Y	2.43
Current VS TTM Avg	+62.42%
Current VS 3Y Avg	-83.49%
Current VS 5Y Avg	-92.70%

ROIC	(67.62%)
ROIC Avg 3Y	(49.79%)
ROIC Avg 5Y	(40.14%)
Current VS 3Y Avg	-35.81%
Current VS 5Y Avg	-68.44%
Current VS 10Y Avg	-43.92%

ROA	(32.53%)
ROA Avg TTM	(8.21%)
ROA Avg 3Y	(8.20%)
Current VS TTM Avg	-296.05%
Current VS 3Y Avg	-296.54%
Current VS 5Y Avg	-344.96%

ROE	(69.47%)
ROE Avg TTM	(61.35%)
ROE Avg 3Y	(53.47%)
Current VS TTM Avg	-13.24%
Current VS 3Y Avg	-29.93%
Current VS 5Y Avg	-63.16%

Net Profit Margin	(651.27%)
Net Profit Margin Avg TTM	(415.03%)
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	-56.92%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	(1.11%)
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	+100.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Tax Rate	(2.73%)
Tax Rate Avg 3Y	(1.94%)
Tax Rate Avg 5Y	(1.29%)
Current VS 3Y Avg	-40.90%
Current VS 5Y Avg	-111.35%
Current VS 10Y Avg	-269.83%